CU20130058A7 - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents

Polipéptidos del factor ix modificados y usos de los mismos

Info

Publication number
CU20130058A7
CU20130058A7 CU2013000058A CU20130058A CU20130058A7 CU 20130058 A7 CU20130058 A7 CU 20130058A7 CU 2013000058 A CU2013000058 A CU 2013000058A CU 20130058 A CU20130058 A CU 20130058A CU 20130058 A7 CU20130058 A7 CU 20130058A7
Authority
CU
Cuba
Prior art keywords
polipeptides
same
modified factor
factor
modified
Prior art date
Application number
CU2013000058A
Other languages
English (en)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130058(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20130058A7 publication Critical patent/CU20130058A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a procedimientos para producir polipéptidos del Factor IX.
CU2013000058A 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos CU20130058A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CU20130058A7 true CU20130058A7 (es) 2013-06-28

Family

ID=43529743

Family Applications (3)

Application Number Title Priority Date Filing Date
CU20120018A CU20120018A7 (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos
CU2013000058A CU20130058A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos
CU2013000057A CU20130057A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CU20120018A CU20120018A7 (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CU2013000057A CU20130057A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (es)
EP (1) EP2461821A4 (es)
JP (1) JP2013500726A (es)
KR (1) KR20120060209A (es)
CN (1) CN102573890A (es)
AU (1) AU2010278721A1 (es)
BR (1) BR112012002072A2 (es)
CA (1) CA2769258A1 (es)
CL (1) CL2012000238A1 (es)
CR (1) CR20120052A (es)
CU (3) CU20120018A7 (es)
DO (1) DOP2012000030A (es)
EA (1) EA201290069A1 (es)
EC (1) ECSP12011637A (es)
GT (1) GT201200023A (es)
IN (1) IN2012DN00908A (es)
MX (1) MX2012001346A (es)
PE (1) PE20121643A1 (es)
SG (1) SG178119A1 (es)
WO (1) WO2011014890A1 (es)
ZA (1) ZA201200716B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074032A1 (en) 2006-12-15 2008-06-19 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR102172133B1 (ko) * 2010-07-30 2020-11-02 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
DK2794665T3 (da) * 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
EP2922871B1 (en) * 2012-11-20 2019-06-19 The University of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
CA2901928C (en) * 2013-03-13 2017-10-10 Eli Lilly And Company Modified canine leptin polypeptides
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
CN109789181A (zh) * 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417341A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
EP2461821A4 (en) 2013-07-03
GT201200023A (es) 2014-01-27
CN102573890A (zh) 2012-07-11
EP2461821A1 (en) 2012-06-13
PE20121643A1 (es) 2012-11-25
CA2769258A1 (en) 2011-02-03
BR112012002072A2 (pt) 2016-11-08
CU20130057A7 (es) 2013-06-28
CL2012000238A1 (es) 2012-10-05
JP2013500726A (ja) 2013-01-10
CU20120018A7 (es) 2012-06-21
DOP2012000030A (es) 2012-02-29
ZA201200716B (en) 2013-07-31
WO2011014890A1 (en) 2011-02-03
CR20120052A (es) 2012-06-04
US20120164130A1 (en) 2012-06-28
ECSP12011637A (es) 2012-02-29
AU2010278721A1 (en) 2012-02-16
KR20120060209A (ko) 2012-06-11
SG178119A1 (en) 2012-03-29
MX2012001346A (es) 2012-02-17
IN2012DN00908A (es) 2015-04-03
EA201290069A1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
CU20130057A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
IL241349B (en) Interleukin-2 mutants for regulatory t cell expansion
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
PA8836801A1 (es) Polipeptidos g-csf de bovino modificados y sus usos
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34538A (es) Heteroarilos y usos de los mismos
HN2010000084A (es) Derivados de sulfonamida
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
BR112013028512A2 (pt) cápsula
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112015012907A2 (pt) composição de cuidado pessoal
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY34018A (es) Derivados glucósidos y usos de los mismos
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
DK2533895T3 (da) Fremgangsmåde til fremstilling af hydrogeneret biodiesel
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
CL2009001624S1 (es) Maquina para preparar bebidas.
BR112013028039A2 (pt) composição de cimento
CR20140124A (es) Metabolitos de transclomifeno y usos de los mismos
UY34670A (es) Planta para la producción de peróxido de hidrógeno y proceso para su uso
GT201000031S (es) Diseño de confitería